Pierrel Logo

Pierrel

Global pharma company specializing in dental anesthetics and contract manufacturing services.

PRL | XMIL

Overview

Corporate Details

ISIN(s):
IT0005549644
LEI:
8156002BC7CB6E3BD403
Country:
Italy
Address:
STRADA STATALE APPIA 7 BIS, 46/48, 81043 CAPUA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Pierrel is a global pharmaceutical company, established in 1948, specializing in the oral health sector. The company's core activities encompass the development, production, registration, and licensing of dental anesthetics and complementary medical devices. Its product portfolio features proprietary brands such as Orabloc®, Ubisestin™, Xylestesin™, and Mepivastesin™, which are distributed in global markets. Operating a production facility authorized by major regulatory bodies, including the EMA and FDA, Pierrel manufactures injectable drugs for its own brands and provides contract manufacturing services to the broader biopharmaceutical industry. The company focuses on delivering innovative solutions for dental professionals worldwide.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-01-24 12:25
Delisting Announcement
Pierrel S.p.A.: OFFERTA PUBBLICA DI ACQUISTO VOLONTARIA TOTALITARIA SULLE AZION…
Italian 249.0 KB
2024-01-17 19:37
Delisting Announcement
Pierrel S.p.A.: OFFERTA PUBBLICA DI ACQUISTO VOLONTARIA TOTALITARIA SULLE AZION…
Italian 262.6 KB
2023-12-20 20:07
Post-Annual General Meeting Information
Pierrel S.p.A.: Comunicato ai sensi dell’art. 41, co. 6 RE, emesso da PRL S.p.A…
Italian 261.4 KB
2023-12-15 21:19
Delisting Announcement
Pierrel S.p.A.: Comunicato ai sensi dell’art. 36 del RE, emesso da PRL SpA
Italian 230.9 KB
2023-12-14 20:16
Pre-Annual General Meeting Information
Pierrel S.p.A.: Comunicato ai sensi degli artt. 36 e 43 del Regolamento adottat…
Italian 227.0 KB
2023-11-29 11:28
Annual / Quarterly Financial Statement
Pierrel S.p.A.: Bilancio d'esercizio al 31.12.2022
Italian 4.9 MB
2023-11-28 21:23
M&A Activity
Pierrel S.p.A.: Comunicato ai sensi dell’art. 36 del RE - emesso da PRL S.p.A. …
Italian 242.8 KB
2023-11-24 23:43
M&A Activity
Pierrel S.p.A.: Comunicato ai sensi dell’art. 38, co. 2 RE,emesso da PRL S.p.A.…
Italian 221.8 KB
2023-11-24 19:28
M&A Activity
Pierrel S.p.A.: IL CDA DI PIERREL APPROVA IL COMUNICATO DELL’EMITTENTE IN REL. …
Italian 256.7 KB
2023-11-22 22:55
Delisting Announcement
Pierrel S.p.A.: PRL S.p.A. OFFERTA PUBBLICA DI ACQUISTO VOLONTARIA TOTALITARIA …
Italian 203.6 KB
2023-11-16 15:43
Post-Annual General Meeting Information
Pierrel S.p.A.: Informazioni essenziali Addendum al patto parasociale – 16 nove…
Italian 310.4 KB
2023-11-16 15:40
M&A Activity
Pierrel S.p.A.: Estratto Addendum al patto parasociale – 16 novembre 2023
Italian 1.2 MB
2023-11-15 11:03
M&A Activity
Pierrel S.p.A.: Comunicato ai sensi dell’art. 38, co. 1, del Regolamento - AVVI…
Italian 133.7 KB
2023-10-31 17:18
Regulatory News Service
Pierrel S.p.A.: Comunicato ai sensi dell’art. 38, co. 1,emesso da PRL S.p.A. e …
Italian 141.2 KB
2023-10-24 11:11
M&A Activity
Pierrel S.p.A.: Comunicato ai sensi dell’art. 102, comma 3, del D.Lgs. 24 febbr…
Italian 215.6 KB

Automate Your Workflow. Get a real-time feed of all Pierrel filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Pierrel via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
AnGes, Inc. Logo
Develops gene-based medicines like HGF gene therapy, DNA vaccines, and NF-kB decoys.
Japan 4563
ANIMALCARE GROUP PLC Logo
Develops & sells veterinary prescription & OTC medicines for professionals worldwide.
United Kingdom ANCR
Annexin Pharmaceuticals AB Logo
Developing Annexin A5 protein to treat vascular, inflammatory, and cancerous diseases.
Sweden ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.
South Korea 065660
Antibiotice S.A. Logo
Develops and manufactures generic medicines and APIs, specializing in anti-infectives.
Romania ATB
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany APPH
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea 397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea 003060
Aprogen, Inc Logo
Develops and manufactures novel biologics and biosimilars for cancer and arthritis treatments.
South Korea 007460
Develops drugs for fibrosis, inflammation, and cancer using NOX inhibitor & CAF modulation tech.
South Korea 293780

Talk to a Data Expert

Have a question? We'll get back to you promptly.